Literature DB >> 32168022

Prevalence of Cervical Cancer Overscreening: Review of a Wellness Registry.

Mary Franklin1, Allison Webel, David Kaelber, Jill Evans, Carol Kelley.   

Abstract

Appropriately matching preventive health services and screenings with patient risk is an important quality indicator. Adherence by both providers and patients to cervical cancer screening guidelines has been inconsistent, resulting in overscreening and increased costs. This study examined the prevalence of cervical cancer overscreening following changes in screening guidelines in a wellness registry database. Cervical cancer overscreening after guideline implementation decreased for 18- to 20-year-old patients from 26.8% to 24.8% (P < .001) and increased for those aged 65 years and older from 11.1% to 12.5% (P = .0005). Black race, Hispanic ethnicity, Medicaid insurance, and the presence of a personal health record were associated with overscreening. Reliability and accuracy of data are a concern when data intended for one purpose, such as clinical care, are used for research. Correctly identifying screening tests in the electronic health record is important so that appropriate screening can be reliably assessed. In this study on the prevalence of cervical cancer overscreening, we used a focused chart review to identify whether screening Pap tests were accurately identified in the electronic medical record. Pap tests were correctly identified as screening in 85% of those aged 18 to 20, and in 74% of those aged 65 and older.

Entities:  

Mesh:

Year:  2020        PMID: 32168022     DOI: 10.1097/CIN.0000000000000610

Source DB:  PubMed          Journal:  Comput Inform Nurs        ISSN: 1538-2931            Impact factor:   1.985


  1 in total

1.  ThinPrep cytologic test combined with HPV typing to evaluate the degree of cervical diseases and the relationship between HPV typing and the pathological results of patients with atypical squamous cells of undetermined significance: a diagnostic test.

Authors:  Ling Wang; Qingxia Song; Ying Liu; Qiang Ou
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.